Drug Trial Radar · NCT02028065
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
Last checked: Nov 20, 2026Latest source record: Apr 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
382
Actual
Start
Jan 3, 2014
Primary completion
Jul 1, 2014
Study completion Jul 1, 2014
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the potential for hypersensitivity symptoms upon repeat exposure to sugammadex. Healthy participants will be randomized to one of three treatment arms: sugammadex 4 mg/kg, sugammadex 16 mg/kg or placebo. Participants will receive 3 single intravenous (IV) doses of their randomized treatment, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3. Participants will be confined at the study center from the day before each dose until completion of the 24-hour post dose assessments.
Conditions
- Hypersensitivity
- Anaphylaxis
Interventions
SugammadexDrug
Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
PlaceboDrug
Placebo administered as a single IV bolus over 10 seconds
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adjudicated Symptoms of HypersensitivityTime frame: Up to approximately 28 days after last dose (approximately 14 weeks)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.